At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Neurobiological Underpinnings of Placebo Response in Depression
In Brief
A Phase 4 clinical trial evaluating Welbutrin XL and Placebo for Depression. Completed, enrolled 76 participants across 1 site.
Detailed Summary
In summary, the proposed research is novel with respect to design, technology, and its multi-level integration probing psychological and neurobiological constructs assumed to be crucially implicated in placebo response and has significant clinical and research implications for the future. Specifically, the future implications include: 1) identification of biomarkers and biosignatures of placebo responders, 2) new possibilities to understanding and manipulating the system, 3) possibly decreasing or eliminating a major confounder in clinical trials and drug development, and 4) refining treatments with novel drugs that decrease (in clinical trial) or increase (in clinical practice) the placebo response.
Study Details
Timeline
Interventions
12.5% of participants will receive Welbutrin XL in phase 1 of the study.
87.5% of subjects will be randomized to placebo in phase 1 of the study.